| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
J. Biol. Chem., Vol. 261, Issue 27, 12665-12674, 09, 1986
PV Hauschka, AE Mavrakos, MD Iafrati, SE Doleman and M Klagsbrun
The mineralized matrix of osseous tissue harbors abundant mitogenic
activity which is extractable by demineralizing solvents. In bovine bone
powder free of blood and cartilage contamination, the volume concentration
of mitogens is up to 20 times greater than in serum. Growth factor activity
in bone extracts was quantitated on quiescent mouse BALB/c/3T3 fibroblasts,
where [3H]thymidine incorporation for 48 h was stimulated up to 200-fold in
a linear, dose-dependent manner. Six distinct bone-derived growth factors
(BDGFs) have been resolved and partially purified (up to 44,000-fold) on
heparin-Sepharose using NaCl gradient elution. Provisionally named by the
NaCl molarity at which they elute, these BDGFs include BDGF-0.45 (25% of
total activity). This factor is heat-stable and sensitive to
dithiothreitol, and displaces 125I-labelled bovine platelet-derived growth
factor in a radioreceptor assay. BDGF-0.45 (approximately 50 ng/g of bone)
is closely related or identical to bovine platelet-derived growth factor.
BDGF-1.1 (10%) has a pI of 5.2 and shows a 16,600-dalton doublet on sodium
dodecyl sulfate- polyacrylamide gel electrophoresis Western blots stained
with antiserum to bovine anionic fibroblast growth factor. Two activities
with high heparin affinity resemble cationic forms of fibroblast growth
factor. BDGF-1.5 is the dominant factor in fetal membranous bone (50%), but
is less abundant in adult bone (20%). BDGF-1.7, a 17,500-18,400-dalton
triplet, is virtually absent in fetal bone (7%) but abundant (30%) in adult
bone and may be related to cartilage derived growth factor. Two minor
activities, BDGF-0.1 (10%) and BDGF-2.0 (7%) have not been characterized.
Proliferation of bovine capillary endothelial cells was strongly supported
by BDGFs 1.1, 1.5, and 1.7, but not by 0.45. These four purified BDGFs and
the crude bone extract were also strongly mitogenic for rat osteoblasts
while depressing alkaline phosphatase specific activity by 2-3-fold. Bone
exhibits the most complex spectrum of growth factor activities of any
tissue yet described. Bone cells and other indigenous cell types must be
considered as possible sources of the BDGFs, in addition to sequestration
from blood. Mechanisms for unmasking or release of BDGFs from the
mineralized matrix resulting in local action on target cells are
undoubtedly important for the development and maintenance of bone tissue.
Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  G. R. Mundy and J. R. Edwards PTH-Related Peptide (PTHrP) in Hypercalcemia J. Am. Soc. Nephrol., April 1, 2008; 19(4): 672 - 675. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-H. Liu, A. Kirschenbaum, S. Yao, G. Liu, S. A. Aaronson, and A. C. Levine Androgen-Induced Wnt Signaling in Preosteoblasts Promotes the Growth of MDA-PCa-2b Human Prostate Cancer Cells Cancer Res., June 15, 2007; 67(12): 5747 - 5753. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Smid, Y. Wang, J. G.M. Klijn, A. M. Sieuwerts, Y. Zhang, D. Atkins, J. W.M. Martens, and J. A. Foekens Genes Associated With Breast Cancer Metastatic to Bone J. Clin. Oncol., May 20, 2006; 24(15): 2261 - 2267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hiraga, A. Myoui, M. E. Choi, H. Yoshikawa, and T. Yoneda Stimulation of Cyclooxygenase-2 Expression by Bone-Derived Transforming Growth Factor-{beta} Enhances Bone Metastases in Breast Cancer Cancer Res., February 15, 2006; 66(4): 2067 - 2073. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Muguruma, S. Yano, S. Kakiuchi, H. Uehara, M. Kawatani, H. Osada, and S. Sone Reveromycin A Inhibits Osteolytic Bone Metastasis of Small-Cell Lung Cancer Cells, SBC-5, through an Antiosteoclastic Activity Clin. Cancer Res., December 15, 2005; 11(24): 8822 - 8828. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G A Clines and T A Guise Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone Endocr. Relat. Cancer, September 1, 2005; 12(3): 549 - 583. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Goya, S. Miyamoto, K. Nagai, Y. Ohki, K. Nakamura, K. Shitara, H. Maeda, T. Sangai, K. Kodama, Y. Endoh, et al. Growth Inhibition of Human Prostate Cancer Cells in Human Adult Bone Implanted into Nonobese Diabetic/Severe Combined Immunodeficient Mice by a Ligand-Specific Antibody to Human Insulin-Like Growth Factors Cancer Res., September 1, 2004; 64(17): 6252 - 6258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. F. Muschler, C. Nakamoto, and L. G. Griffith Engineering Principles of Clinical Cell-Based Tissue Engineering J. Bone Joint Surg. Am., July 1, 2004; 86(7): 1541 - 1558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hiraga, P. J. Williams, A. Ueda, D. Tamura, and T. Yoneda Zoledronic Acid Inhibits Visceral Metastases in the 4T1/luc Mouse Breast Cancer Model Clin. Cancer Res., July 1, 2004; 10(13): 4559 - 4567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Roodman Mechanisms of Bone Metastasis N. Engl. J. Med., April 15, 2004; 350(16): 1655 - 1664. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Thomas, P. Moffatt, P. Salois, M.-H. Gaumond, R. Gingras, E. Godin, D. Miao, D. Goltzman, and C. Lanctot Osteocrin, a Novel Bone-specific Secreted Protein That Modulates the Osteoblast Phenotype J. Biol. Chem., December 12, 2003; 278(50): 50563 - 50571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Fohr, C. R. Dunstan, and M. J. Seibel Markers of Bone Remodeling in Metastatic Bone Disease J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5059 - 5075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Santini, U. Vespasiani Gentilucci, B. Vincenzi, A. Picardi, F. Vasaturo, A. La Cesa, N. Onori, S. Scarpa, and G. Tonini The antineoplastic role of bisphosphonates: from basic research to clinical evidence Ann. Onc., October 1, 2003; 14(10): 1468 - 1476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Okada, A. Montero, X. Zhang, T. Sobue, J. Lorenzo, T. Doetschman, J. D. Coffin, and M. M. Hurley Impaired Osteoclast Formation in Bone Marrow Cultures of Fgf2 Null Mice in Response to Parathyroid Hormone J. Biol. Chem., May 30, 2003; 278(23): 21258 - 21266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Yonou, N. Kanomata, M. Goya, T. Kamijo, T. Yokose, T. Hasebe, K. Nagai, T. Hatano, Y. Ogawa, and A. Ochiai Osteoprotegerin/Osteoclastogenesis Inhibitory Factor Decreases Human Prostate Cancer Burden in Human Adult Bone Implanted into Nonobese Diabetic/Severe Combined Immunodeficient Mice Cancer Res., May 1, 2003; 63(9): 2096 - 2102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-M. Kakonen, K. S. Selander, J. M. Chirgwin, J. J. Yin, S. Burns, W. A. Rankin, B. G. Grubbs, M. Dallas, Y. Cui, and T. A. Guise Transforming Growth Factor-beta Stimulates Parathyroid Hormone-related Protein and Osteolytic Metastases via Smad and Mitogen-activated Protein Kinase Signaling Pathways J. Biol. Chem., June 28, 2002; 277(27): 24571 - 24578. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Dallas, J. L. Rosser, G. R. Mundy, and L. F. Bonewald Proteolysis of Latent Transforming Growth Factor-beta (TGF-beta )-binding Protein-1 by Osteoclasts. A CELLULAR MECHANISM FOR RELEASE OF TGF-beta FROM BONE MATRIX J. Biol. Chem., June 7, 2002; 277(24): 21352 - 21360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Winding, R. NicAmhlaoibh, H. Misander, P. Hoegh-Andersen, T. L. Andersen, C. Holst-Hansen, A.-M. Heegaard, N. T. Foged, N. Brunner, and J.-M. Delaisse Synthetic Matrix Metalloproteinase Inhibitors Inhibit Growth of Established Breast Cancer Osteolytic Lesions and Prolong Survival in Mice Clin. Cancer Res., June 1, 2002; 8(6): 1932 - 1939. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. N. Pearse, E. M. Sordillo, S. Yaccoby, B. R. Wong, D. F. Liau, N. Colman, J. Michaeli, J. Epstein, and Y. Choi Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression PNAS, September 13, 2001; (2001) 201394498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hiraga, P. J. Williams, G. R. Mundy, and T. Yoneda The Bisphosphonate Ibandronate Promotes Apoptosis in MDA-MB-231 Human Breast Cancer Cells in Bone Metastases Cancer Res., June 1, 2001; 61(11): 4418 - 4424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. M. Luger, P. Honore, M. A. C. Sabino, M. J. Schwei, S. D. Rogers, D. B. Mach, D. R. Clohisy, and P. W. Mantyh Osteoprotegerin Diminishes Advanced Bone Cancer Pain Cancer Res., May 1, 2001; 61(10): 4038 - 4047. [Abstract] [Full Text]
|
|
|
|
|
|
H. Kawaguchi, K. Nakamura, Y. Tabata, Y. Ikada, I. Aoyama, J. Anzai, T. Nakamura, Y. Hiyama, and M. Tamura Acceleration of Fracture Healing in Nonhuman Primates by Fibroblast Growth Factor-2 J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 875 - 880. [Abstract] [Full Text]
|
|
|
|
 |
|
 Md. Muniruzzaman, Y. Tabata, and Y. Ikada Physicochemical Properties of Basic Fibroblast Growth Factor-Gelatin Complex Journal of Bioactive and Compatible Polymers, September 1, 2000; 15(5): 365 - 375. [Abstract] [PDF]
|
|
|
|
 |
|
 S. Varghese, S. Rydziel, and E. Canalis Basic Fibroblast Growth Factor Stimulates Collagenase-3 Promoter Activity in Osteoblasts through an Activator Protein-1-Binding Site Endocrinology, June 1, 2000; 141(6): 2185 - 2191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K Fuller, J. Lean, K. Bayley, M. Wani, and T. Chambers A role for TGFbeta(1) in osteoclast differentiation and survival J. Cell Sci., January 7, 2000; 113(13): 2445 - 2453. [Abstract] [PDF]
|
|
|
|
|
|
H. Liang, S. Pun, and T. J. Wronski Bone Anabolic Effects of Basic Fibroblast Growth Factor in Ovariectomized Rats Endocrinology, December 1, 1999; 140(12): 5780 - 5788. [Abstract] [Full Text]
|
|
|
|
|
|
M. Suzawa, Y. Takeuchi, S. Fukumoto, S. Kato, N. Ueno, K. Miyazono, T. Matsumoto, and T. Fujita Extracellular Matrix-Associated Bone Morphogenetic Proteins Are Essential for Differentiation of Murine Osteoblastic Cells in Vitro Endocrinology, May 1, 1999; 140(5): 2125 - 2133. [Abstract] [Full Text]
|
|
|
|
|
|
G. A. Rodan Bone homeostasis PNAS, November 10, 1998; 95(23): 13361 - 13362. [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. Dhodapkar, E. Abe, A. Theus, M. Lacy, J. K. Langford, B. Barlogie, and R. D. Sanderson Syndecan-1 Is a Multifunctional Regulator of Myeloma Pathobiology: Control of Tumor Cell Survival, Growth, and Bone Cell Differentiation Blood, April 15, 1998; 91(8): 2679 - 2688. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. A. Guise and G. R. Mundy Cancer and Bone Endocr. Rev., February 1, 1998; 19(1): 18 - 54. [Abstract] [Full Text]
|
|
|
|
|
|
Z. Schwartz, V. L. Sylvia, D. D. Dean, and B. D. Boyan The Synergistic Effects of Vitamin D Metabolites and Transforming Growth Factor-{beta} on Costochondral Chondrocytes Are Mediated by Increases in Protein Kinase C Activity Involving Two Separate Pathways Endocrinology, February 1, 1998; 139(2): 534 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Takigawa, T. Okawa, H.-O. Pan, C. Aoki, K. Takahashi, J.-D. Zue, F. Suzuki, and A. Kinoshita Insulin-Like Growth Factors I and II Are Autocrine Factors in Stimulating Proteoglycan Synthesis, a Marker of Differentiated Chondrocytes, Acting through Their Respective Receptors on a Clonal Human Chondrosarcoma-Derived Chondrocyte Cell Line, HCS-2/8 Endocrinology, October 1, 1997; 138(10): 4390 - 4400. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Hill, A. Tumber, and M. C. Meikle Multiple Extracellular Signals Promote Osteoblast Survival and Apoptosis Endocrinology, September 1, 1997; 138(9): 3849 - 3858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. LIETMAN, M. YANAGISHITA, T. K. SAMPATH, and A. H. REDDI Stimulation of Proteoglycan Synthesis in Explants of Porcine Articular Cartilage by Recombinant Osteogenic Protein-1 (Bone Morphogenetic Protein-7) J. Bone Joint Surg. Am., August 1, 1997; 79(8): 1132 - 7. [Abstract] [Full Text]
|
|
|
|
|
|
S. L. Godwin and S. P. Soltoff Extracellular Calcium and Platelet-derived Growth Factor Promote Receptor-mediated Chemotaxis in Osteoblasts through Different Signaling Pathways J. Biol. Chem., April 25, 1997; 272(17): 11307 - 11312. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q.-R. Chen, C. Miyaura, S. Higashi, M. Murakami, I. Kudo, S. Saito, T. Hiraide, Y. Shibasaki, and T. Suda Activation of Cytosolic Phospholipase A2 by Platelet-derived Growth Factor Is Essential for Cyclooxygenase-2-dependent Prostaglandin E2 Synthesis in Mouse Osteoblasts Cultured with Interleukin-1 J. Biol. Chem., February 28, 1997; 272(9): 5952 - 5958. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. B. TRIPPEL, R. D. COUTTS, T. A. EINHORN, G. R. MUNDY, and R. G. ROSENFELD Instructional Course Lectures, The American Academy of Orthopaedic Surgeons - Growth Factors as Therapeutic Agents*{{dagger}} J. Bone Joint Surg. Am., August 1, 1996; 78(8): 1272 - 86. [Full Text]
|
|
|
|
|
|
E. J. Feres-Filho, G. B. Menassa, and P. C. Trackman Regulation of Lysyl Oxidase by Basic Fibroblast Growth Factor in Osteoblastic MC3T3-E1 Cells J. Biol. Chem., March 15, 1996; 271(11): 6411 - 6416. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Poulin, K. Patrie, M. Botelho, R. Tassava, and I. Chiu Heterogeneity in the expression of fibroblast growth factor receptors during limb regeneration in newts (Notophthalmus viridescens) Development, January 10, 1993; 119(2): 353 - 361. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Wozney, V Rosen, A. Celeste, L. Mitsock, M. Whitters, R. Kriz, R. Hewick, and E. Wang Novel regulators of bone formation: molecular clones and activities Science, December 16, 1988; 242(4885): 1528 - 1534. [Abstract] [PDF]
|
|
|
|
|
|
J Folkman and M Klagsbrun Angiogenic factors Science, January 23, 1987; 235(4787): 442 - 447. [Abstract] [PDF]
|
|
|
|
|
|
R. N. Pearse, E. M. Sordillo, S. Yaccoby, B. R. Wong, D. F. Liau, N. Colman, J. Michaeli, J. Epstein, and Y. Choi Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression PNAS, September 25, 2001; 98(20): 11581 - 11586. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |
